Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21765581 | 0.93 | PDE4B (0.51) | PDE4BPKMPOLBOPRK1KDM4E | |
| SCHEMBL15689099 | 0.92 | POLB (0.49) | PDE4BDYRK1APOLBKDM4EMAPT | |
| SCHEMBL29613011 | 0.92 | POLB (0.49) | PDE4BDYRK1APOLBKDM4EMAPT | |
| SCHEMBL15110067 | 0.90 | ALOX15 (0.50) | PDE4BPOLBOPRK1KDM4EMAPT | |
| SCHEMBL21460241 | 0.90 | ALOX15 (0.53) | PDE4BPOLBOPRK1KDM4EMAPT | |
| SCHEMBL30726325 | 0.90 | ALOX15 (0.53) | PDE4BPOLBOPRK1KDM4EMAPT | |
| SCHEMBL16873815 | 0.88 | PDE4B (0.44) | PDE4BPOLBKDM4EMAPTNR2F2 | |
| SCHEMBL21949165 | 0.88 | ALOX15 (0.55) | PDE4BPOLBOPRK1KDM4EMAPT | |
| SCHEMBL21724833 | 0.88 | OPRK1 (0.46) | PDE4BOPRK1MAPK1IRAK4 | |
| SCHEMBL30201761 | 0.88 | OPRK1 (0.46) | PDE4BOPRK1MAPK1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300977-A1 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | INTELLIA THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| CN-117940426-A | DNA-dependent protein kinase inhibitors, compositions and uses thereof | 英特利亚治疗股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4323360-A1 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | Intellia Therapeutics, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221696-A1 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | INTELLIA THERAPEUTICS, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| EP-2582703-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2013-04-24 | — | — | EP | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| WO-2011157397-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-12-22 | — | — | WO | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300977-A1 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | CHEK1, DCK, CHEK2 | PDE4B 2038/4885PKM 1214/4885DYRK1A 983/4885 |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | PDE4B 3179/4885PKM 1383/4885DYRK1A 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.